2.71
-0.04(-1.45%)
Currency In USD
| Previous Close | 2.75 |
| Open | 2.7 |
| Day High | 2.74 |
| Day Low | 2.67 |
| 52-Week High | 4.32 |
| 52-Week Low | 1.05 |
| Volume | 5.61M |
| Average Volume | 3.2M |
| Market Cap | 581.73M |
| PE | -7.97 |
| EPS | -0.34 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 1.95 |
| Change | -0.04 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $112.64 as of June 01, 2025 at a share price of $2.71. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 3 years ago, it would be worth $1,097.17 as of June 01, 2025 at a share price of $2.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
May 29, 2025 2:40 AM GMT
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
May 28, 2025 8:02 PM GMT
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
GlobeNewswire Inc.
May 28, 2025 8:01 PM GMT
Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment from FDA sup